156371-85-6

Basic information

• Product Name: (S)-3-Mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester
• Synonyms: (3S)-N-Boc-3-Mercapto-1-pyrrolidine;(S)-tert-Butyl 3-Mercaptopyrrolidine-1-carboxylate
• CAS NO: 156371-85-6
• Molecular Formula: C9H17NO2S
• Molecular Weight: 203.30178
• Mol File: 156371-85-6.mol

Chemical Properties

• Boiling Point: 275.1±33.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.43±0.20(Predicted)
• CAS DataBase Reference: (S)-3-Mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-Mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester(156371-85-6)
• EPA Substance Registry System: (S)-3-Mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester(156371-85-6)

Safety Data

• Hazardous Substances Data: 156371-85-6(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
(S)-3-Mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester is used as a building block for the synthesis of pharmaceuticals due to its unique structure and reactivity. Its sulfur-containing amino acid derivative nature allows for the development of novel therapeutic agents with potential biological activities.
Used in Drug Discovery:
In the field of drug discovery, (S)-3-Mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester is used as a key intermediate in the design and synthesis of new drug candidates. Its versatility and stability make it an attractive component for the creation of molecules with potential therapeutic properties.
Used in Organic Synthesis:
(S)-3-Mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester is used as a versatile intermediate in organic synthesis for the preparation of various organic compounds. The protection of the carboxylic acid group by the tert-butyl ester allows for selective reactions and the synthesis of complex molecular structures.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (S)-3-Mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester is used as a key component in the synthesis of active pharmaceutical ingredients. Its unique properties and reactivity contribute to the development of innovative medicines with improved efficacy and safety profiles.

Upstream product

• 132945-75-6 (S)-tert-butyl 3-(methylsulfonyloxy)pyrrolidine-1-carboxylate 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 935845-19-5 (R)-tert-butyl 3-(acetylthio)pyrrolidine-1-carboxylate 
• 444100-61-2 (S)-tert-butyl 3-(acetylthio)pyrrolidine-1-carboxylate 
• 347189-17-7 N-tert-butoxycarbonyl-2-hydroxypyrrolidine 
• 507-09-5 tiolacetic acid 
• 1972-28-7 diethylazodicarboxylate 

Relevant articles and documents

BROAD-SPECTRUM CARBAPENEMS

The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY

This invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2,R3, R4, R5, R6, R7, k, m, n, p, q, r and s are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity.

Pleuromutilin derivatives having a purine ring. Part 2: Influence of the central spacer on the antibacterial activity against Gram-positive pathogens

Structural modification of the 4-piperidinethio moiety, as a spacer of the first pleuromutilin analogues 2A and 2B having a purine ring, led to discovery of the novel pleuromutilin derivatives 14B and 17B. These compounds with good solubility in water showed promising in vitro antibacterial activity against various Gram-positive bacteria including MRSA, PRSP, and VRE and have potent in vivo efficacy.

Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors

Potent SAH analogues with constrained homocysteine units have been designed and synthesized as inhibitors of human DNMT enzymes. The five membered (2S,4S)-4-mercaptopyrrolidine-2-carboxylic acid, in 1a, was a good replacement for homocysteine, while the corresponding six-member counterpart was less active. Further optimization of 1a, changed the selectivity profile of these inhibitors. A Chloro substituent at the 2-position of 1a, compound 1d, retained potency against DNMT1, while N6 alkylation, compound 7a, conserved DNMT3b2 activity. The concomitant substitutions of 1a at both 2- and N6 positions reduced activity against both enzymes.

NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS

The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Naphthostyrils

Disclosed are novel naphthostyrils of formula 1These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical compositions containing such compounds, methods for the treatment and/or prevention of cancer using such compositions, and intermediates useful in the preparation of the compounds of formula I.

Heterocyclic compounds useful as NMDA receptor selective subtype blockers

The invention relates to compounds of formula wherein Ar1 is pyridyl or phenyl, substituted by hydroxy, lower alkyl, halogen, amino, nitro, benzyloxy or lower alkoxy-lower alkoxy, or is the group wherein Z1 is a five membered heteroc